AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC
Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.
Neoadjuvant Durvalumab John Heymach Adjuvant Durvalumab Partnership With Non Small Cell Lung Cancer Early Stage Lung Cancer
Source: onclive.com